[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641888":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":26,"responsibleParty":67,"collaborators":10,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":71,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":83,"studyType":84,"phases":10,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":60,"whyStopped":10,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients diagnosed with MASLD",null,"Consecutive patients diagnosed with MASLD at any degree of fibrosis between the ages of 20 and 80 will be included. The main variable will be the degree of frailty assessed by the LFI and the Fried Index.",[13],{"name":14,"affiliation":15,"role":16},"Eva Roman","Institut de Recerca IR Sant Pau","PRINCIPAL_INVESTIGATOR",[18,23],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Eva Román, Digestive Pathology Nurse","CONTACT","0034630818580","ERoman@santpau.cat",{"name":24,"role":20,"phone":10,"phoneExt":10,"email":25},"German Soriano, Digestive Pathology MD","gsoriano@santpau.cat",[27,59],{"facility":28,"status":29,"city":30,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Hospital de la Santa Creu i Sant Pau","NOT_YET_RECRUITING","Barcelona","08031","Spain","ES",{"type":35,"coordinates":36},"Point",[37,38],2.15899,41.38879,{"lat":38,"lon":37},[41,42,45,47,49,51,53,55,57],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},{"name":43,"role":44,"phone":10,"phoneExt":10,"email":10},"Elisabeth Pérez-Chust, Internal Medicine Nurse","SUB_INVESTIGATOR",{"name":46,"role":44,"phone":10,"phoneExt":10,"email":10},"Rosalía Santesmases, EUI Sant Pau Nurse",{"name":48,"role":44,"phone":10,"phoneExt":10,"email":10},"Maria Poca, Digestive Pathology MD PhD",{"name":50,"role":44,"phone":10,"phoneExt":10,"email":10},"German Soriano, Digestive Pathology MD PhD",{"name":52,"role":44,"phone":10,"phoneExt":10,"email":10},"Berta Cuyàs, Digestive Pathology MD PhD",{"name":54,"role":44,"phone":10,"phoneExt":10,"email":10},"Idoia Genua, Endocrinology and Nutrition MD",{"name":56,"role":44,"phone":10,"phoneExt":10,"email":10},"Marc Pons-Tarín, Microbiome Department Member",{"name":58,"role":44,"phone":10,"phoneExt":10,"email":10},"Zoraida Moreno-Weidmann, Cardiology MD",{"facility":28,"status":60,"city":30,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":61,"geoPoint":63,"contacts":64},"RECRUITING",{"type":35,"coordinates":62},[37,38],{"lat":38,"lon":37},[65],{"name":19,"role":20,"phone":66,"phoneExt":10,"email":22},"0034-630818580",{"type":68,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100641888","impact-of-steatotic-liver-disease-associated-with-metabolic-dysfunction-masld-on-frailty-cognition-and-quality-of-life-a-gender-sensitive-approach-towards-a-comprehensive-and-equitable-perspective-100641888",false,"NCT07652892","Impact of Steatotic Liver Disease Associated With Metabolic Dysfunction (MASLD) on Frailty, Cognition, and Quality of Life. A Gender-sensitive Approach Towards a Comprehensive and Equitable Perspective.","IIBSP-MAS-2025-133","MASLD","Inclusion Criteria:\n\n* Patients will be included who are able to provide informed consent and actively participate in periodic assessments.\n\nExclusion Criteria:\n\n* Risky alcohol consumption:\n\n\\> 30 g\u002Fday in men and \\> 20 g\u002Fday in women. AUDIT score: \\> 7 points in men, \\> 5 in women.\n\n* Other liver diseases (viral hepatitis, autoimmune hepatitis, etc.).\n* Advanced neurodegenerative diseases or severe psychiatric disorders.\n* Severe comorbidities or treatments that, in the researchers' judgment, may affect frailty and quality of life more than metabolic syndrome and liver disease.","ALL","20 Years","80 Years",{"count":81,"type":82},140,"ESTIMATED","12 Months","OBSERVATIONAL","The goal of this observational study is to determine the differences in the prevalence, characteristics and evolution of frailty between men and women diagnosed with MASLD, and to establish its relationship with clinical, functional, hormonal and social parameters.",[87],"Steatosis of Liver",[89],"A condition characterized by the accumulation of fat in the liver, which is closely linked to metabolic disorders and occurs with low or no alcohol consumption.","2026-06-11",{"date":92,"type":93},"2026-06-17","ACTUAL",{"date":95,"type":82},"2026-05-26",{"date":97,"type":82},"2028-05-25",{"name":5,"class":6},2]